Engineered liposomes to deliver nucleic acid mimics in Escherichia coli

Data de publicação: Data Ahead of Print:

Autores da FMUP

  • Maria Do Céu Fontes Herdeiro Figueiredo

    Autor

Participantes de fora da FMUP

  • Moreira, L
  • Guimaraes, NM
  • Pereira, S
  • Santos, R.
  • Loureiro, J.
  • Ferreira, RM
  • Pereira, M.
  • Azevedo, N.

Unidades de investigação

Abstract

Antisense oligonucleotides (ASOs) composed of nucleic acid mimics (NAMs) monomers are considered as po-tential novel therapeutic drugs against bacterial infections. However, bacterial envelopes are generally imper-meable to naked oligonucleotides. Herein, liposomes loaded with NAMs-modified oligonucleotides (LipoNAMs) were evaluated to deliver ASOs in Escherichia coli. Specifically, we tested several surface modifications that included methoxyPEG conjugated to different lipid anchors or modification of the PEG distal ends with mal-eimide groups and antibodies. MethoxyPEG coated LipoNAMs showed low delivery efficiency for most bacteria, but maleimide-functionalized PEG LipoNAMs were able to deliver ASOs to nearly half of the bacterial population. Conjugation of antibodies to maleimide-functionalized PEG LipoNAMs increased 1.3-fold the delivery efficiency, enhancing the selectivity towards E. coli and biocompatibility. This work demonstrated for the first time that the coupling of antibodies to PEGylated liposomes can significantly improve the delivery of ASOs in E. coli, which might bring alternative routes for the treatment of bacterial infections in the future.

Dados da publicação

ISSN/ISSNe:
1873-4995, 0168-3659

Journal of Controlled Release  Elsevier

Tipo:
Article
Páginas:
489-500
Link para outro recurso:
www.scopus.com

Citações Recebidas na Scopus: 6

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • Antisense oligonucleotides; Cationic liposomes; PEGylation; Immunoliposomes; Nucleic acid analogues; bacteria

Financiamento

Proyectos asociados

Unravelling Helicobacter pylori strategies to disrupt cell-cell junctions

Investigador Principal: Maria do Céu Fontes Herdeiro Figueiredo

Estudo Clínico Académico (Helicobacter) . 2019

Immune checkpoint inhibitors for the treatment of gastric cancer

Investigador Principal: Maria do Céu Fontes Herdeiro Figueiredo

Estudo Clínico Académico . 2021

Evaluation of the use of Helicobacter pylori genotypes and gastric microbiota markers to identify individuals at high risk of gastric carcinoma

Investigador Principal: Maria do Céu Fontes Herdeiro Figueiredo

Estudo Clínico Académico . 2021

Citar a publicação

Partilhar a publicação